Related Experiment Video
Updated: Jun 20, 2026
10:21
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
[TNF-alpha blocking therapy in chronic inflammatory bowel disease].
1Szegedi Tudományegyetem, Altalános Orvostudományi Kar, I. Belgyógyászati Klinika, Szeged. mot@inlst.szote.u-szeged.hu
Orvosi Hetilap
|September 11, 2009
Summary
Tumor necrosis factor-alpha (TNF-a) blocking therapies like infliximab and adalimumab are effective for inflammatory bowel disease. However, a significant portion of patients do not respond to these treatments.
Area of Science:
- Gastroenterology and Immunology
- Pharmacology and Therapeutics
Background:
- Tumor necrosis factor-alpha (TNF-a) blocking therapies have revolutionized inflammatory bowel disease (IBD) treatment.
- Infliximab and adalimumab demonstrate efficacy in moderate to severe Crohn's disease and ulcerative colitis.
Purpose of the Study:
- To evaluate the effectiveness of TNF-a blocking therapies in therapy-resistant IBD patients.
- To compare infliximab and adalimumab in treating Crohn's disease and ulcerative colitis.
Main Methods:
- Review of clinical trial data for infliximab and adalimumab in IBD.
- Analysis of treatment response rates in therapy-resistant populations.
Main Results:
- Both infliximab and adalimumab show effectiveness in Crohn's disease and ulcerative colitis.
- 20-30% of Crohn's disease patients and 30-40% of ulcerative colitis patients exhibit resistance to these therapies.
- No direct comparative studies exist, but general considerations suggest similar effectiveness between infliximab and adalimumab.
Conclusions:
- TNF-a inhibitors offer significant benefits for IBD patients.
- A notable percentage of patients remain resistant to current TNF-a blocking therapies.
- Further comparative studies are needed to definitively establish differences in efficacy between infliximab and adalimumab.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.